Skip to content

Annexon ANNX Total Current Liabilities

Total Current Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.11B+43.2%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$38.28M+126%
Omeros logo
OmerosOMER
$59.44M-28.6%
Vor Biopharma logo
Vor BiopharmaVOR
$16.08M-3.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$35.15M+28.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$57.71M-18.6%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$843.79M+223%
Enterprise value$694.02M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's total current liabilities?
Annexon (ANNX) reported total current liabilities of $35.94M in Q1 2026.
How has Annexon's total current liabilities changed year-over-year?
Annexon's total current liabilities increased by 7.1% year-over-year, from $33.55M to $35.94M.
What is the long-term trend for Annexon's total current liabilities?
Over 5 years (2020 to 2025), Annexon's total current liabilities has grown at a 32.0% compound annual growth rate (CAGR), from $10.62M to $42.63M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.